By Josh Beckerman
Shares of Moleculin Biotech pared earlier gains after the pharmaceutical company announced a $3.5 million registered direct offering and concurrent private placement.
The stock was recently up 14%, to $1.22, midday Tuesday. Shares had risen to an intraday high of $1.64 following Monday's withdrawal of a December filing for public offering of stock and warrants.
Volume was more than 33.4 million shares, compared with a 65-day average of 4.3 million.
The company said Tuesday afternoon that it entered an agreement with an institutional investor to sell 3.27 million shares or pre-funded warrants in lieu thereof, and 6.54 million warrants, at a combined price of $1.07 a share and accompanying warrants.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 25, 2025 13:09 ET (18:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。